Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Mikhail N Kosiborod,Mark C Petrie,Barry A Borlaug,Javed Butler,Melanie J Davies,G Kees Hovingh,Dalane W Kitzman,Daniél V Møller,Marianne B Treppendahl,Subodh Verma,Thomas J Jensen,Karoline Liisberg,Marie L Lindegaard,Walter Abhayaratna,Fozia Z Ahmed,Tuvia Ben-Gal,Vijay Chopra,Justin A Ezekowitz,Michael Fu,Hiroshi Ito,Małgorzata Lelonek,Vojtěch Melenovský,Bela Merkely,Julio Núñez,Eduardo Perna,Morten Schou,Michele Senni,Kavita Sharma,Peter van der Meer,Dirk Von Lewinski,Dennis Wolf,Sanjiv J Shah,STEP-HFpEF DM Trial Committees and Investigators,Daniel Piskorz,Cesar Javier Zaidman,Eduardo Roque Perna,Sonia Hermida,Claudio Majul,Paula Perez Terns,Dirk von Lewinski,Christopher Adlbrecht,Johann Auer,Evelyn Fließer-Görzer,Paul Poirier,Ram Vijayaraghavan,Louis Yao,Yaariv Khaykin,Jonathan Howlett,Amritanshu-Shekhar Pandey,Yves Robitaille,Vojtech Melenovsky,Alica Vesela,Daniel Rob,Jan Mácha,Christoph Axthelm,Frank Edelmann,Stefan Störk,Rolf Wachter,Holger Eggebrecht,Andreas Hagenow,Béla Merkely,József Lippai,Tímea Tanczer,Gergely György Nagy,Géza Lupkovics,Noémi Nyolczas,Tibor Fülöp,László Könyves,András Papp,Imre Szakál,Devendra Kumar Agarwal,Vimal K Mehta,Pravesh Vishwakarma,Sandeep Bansal,Jitendra Pal Singh Sawhney,V K Chopra,Vinod Vijan,Abraham Oomman,Jabir Abdullakutty,Yaron Arbel,Michael Shechter,Rabea Asleh,Shaul Atar,Antonio Iaconelli,Paolo Severino,Marco Metra,Stefano Genovese,Alessandro Fucili,Masayuki Hosoi,Takashi Matsumoto,Tomofumi Takaya,Tadashi Igarashi,Takuo Nakagami,Kenji Ando,Moriaki Inoko,Carlos da Fonseca,Jose Drost,Iris Westendorp,Senan Hammadi,Malgorzata Lelonek,Pawel Balsam,Krzysztof Cymerman,Anna Tomaszuk-Kazberuk,Aleksander Zurakowski,Danuta Wronska,Julio Núñez Villota,José Ramón González Juanatey,Silvia Gómez Moreno,Christina Christersson,Mark Petrie,Fozia Ahmed,Ross Campbell,Ify Mordi,Piers Clifford,Paul Foley,Prathap Kanagala,Steven Lupovitch,Michael Pursley,Ashwini K Davuluri,Michael Fong,Vishnu Garla,Mohammad Tahir,Suhail Khadra,Mikhail Kosiborod,Dalane Kitzman,Chen Chow,Sunit-Preet Chaudhry,Barry Borlaug,Roshanak Markley,Joseph Thibodeau,Steven Heatherly,Bruce Iteld,Keith Miller,Mubashir A Qazi,William Eaves,Anil Chhabra,Ambarish Pandey,Ravi Patel,Ahmad Talal Alhammouri,Mary Katherine Lawrence,Melanie Davies,Sanjiv Shah,Steen Abildstrøm,Marianne Bach Treppendahl,Kees Hovingh,Daniél Vega Møller,Justin Ezekowitz,Julio Nunez Villota
DOI: https://doi.org/10.1056/NEJMoa2313917
2024-04-18
Abstract:Background: Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes. Methods: We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. Results: A total of 616 participants underwent randomization. The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001), and the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001). The results for the confirmatory secondary end points favored semaglutide over placebo (estimated between-group difference in change in 6-minute walk distance, 14.3 m [95% CI, 3.7 to 24.9; P = 0.008]; win ratio for hierarchical composite end point, 1.58 [95% CI, 1.29 to 1.94; P<0.001]; and estimated treatment ratio for change in CRP level, 0.67 [95% CI, 0.55 to 0.80; P<0.001]). Serious adverse events were reported in 55 participants (17.7%) in the semaglutide group and 88 (28.8%) in the placebo group. Conclusions: Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, NCT04916470.).